Invitae Corp
Healthcare · Services-Medical Laboratories · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $123.7M | $103.6M | $279.6M | $216.8M | $147.7M | $68.2M |
| Operating income | −$213.2M | −$112.4M | −$652.2M | −$244.1M | −$122.6M | −$27.3M |
| Net income | −$181.9M | −$109.5M | −$602.2M | −$242.0M | −$129.4M | −$26.9M |
| Total assets | $1.95B | $4.92B | $3.43B | $781.6M | $283.0M | $211.1M |
| Total liabilities | $1.85B | $1.94B | $1.45B | $402.0M | $121.1M | $89.3M |
| Equity | $101.8M | $2.98B | $1.98B | $379.6M | $161.8M | $121.8M |
| EPS (diluted) | $-13.18 | $-1.80 | $-4.47 | $-2.66 | — | — |
| Shares out. | 228.4M | 196.7M | 99.0M | 76.8M | 53.7M | 42.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −172.4%
- Net margin
- −147.0%
- Return on equity
- −178.6%
- Return on assets
- −9.3%
- Return on capital (ROCE)
- −11.6%
- Liabilities / assets
- 94.8%
- Debt / equity
- 18.19×
- Book value / share
- $0.45
- Revenue growth (YoY)
- 19.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -6.77distress
- Accruals / assets
- 15.9%high accruals
- Beneish M-Score
- -1.73elevated
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 6 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Beneish M-Score elevated — earnings-manipulation screen flag
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ark Investment Management LlcPassive (13G)Jan 10, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Nussbaum Robert LOfficer — Chief Medical Officer | Dec 20, 2023 | Tax withholding | 17,404 | $0.65 |
| Brida ThomasOfficer — See Remarks | Dec 20, 2023 | Tax withholding | 17,404 | $0.65 |
| Sholehvar DavidOfficer — Chief Operating Officer | Nov 13, 2023 | Grant | 850,000 | $0.00 |
| Schrank Ana J.Officer — Chief Financial Officer | Oct 2, 2023 | Grant | 850,000 | $0.00 |
| Guigley Robert M.Officer — Chief Commercial Officer | Sep 23, 2023 | Grant | 850,000 | $0.00 |
| Nussbaum Robert LOfficer — Chief Medical Officer | Jun 13, 2023 | Sell | 7,086 | $1.38 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Bankruptcy or receivership · Completed an acquisition or disposition · Modified shareholder rights · Director / officer changeAug 8, 2024
- Regulation FD disclosureJul 31, 2024
- Regulation FD disclosureJul 1, 2024
- Regulation FD disclosureJun 4, 2024
- Entered a material agreement · Regulation FD disclosureMay 2, 2024
- Regulation FD disclosureApr 4, 2024
- Results of operations · Regulation FD disclosureMar 6, 2024
- Entered a material agreement · Bankruptcy or receivership · Debt acceleration / triggering event · Regulation FD disclosure · Other material eventFeb 14, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AJan 10, 2025
- 8-KAug 8, 2024
- 8-KJul 31, 2024
- 8-KJul 1, 2024
- 8-KJun 4, 2024
- 8-KMay 2, 2024
- 8-KApr 4, 2024
- 8-KMar 6, 2024
- 25-NSEFeb 21, 2024
- 8-KFeb 14, 2024
- SC 13G/ASCHEDULE 13G/AFeb 13, 2024
- SC 13G/AFeb 13, 2024
- 8-KFeb 6, 2024
- SC 13G/AAMENDMENT NO. 4Feb 5, 2024
- SC 13G/AJan 29, 2024
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.